Our partner OmniActive Health Technologies (OmniActive) announced the outcomes of a new study on Capsimax®, showing significant increases in resting energy expenditure (REE) post-consumption of Capsimax.
A randomized, double-blind, placebo-controlled metabolic rate study that involved 28 healthy adults was presented at the Global Summit on Obesity, Diet, and Nutrition and published in the Journal of Obesity and Therapeutics.
The primary objective was to measure changes in REE from baseline to post-treatment at 1, 2, 3, and 4 hours in comparison to placebo.
REE represents the amount of energy expended by a person at rest to maintain the basic and vital functions of the body and accounts for up to 70% of total energy expenditure. Increases in energy expenditure have been linked to a reduction in body fat.
Findings specific to increases in REE are consistent with their previously published study showing similar benefits of Capsimax, an encapsulated, concentrated extract of capsaicinoids from red chili peppers (Capsicum annum). In their first metabolic rate study, Capsimax demonstrated that it increased metabolic rate in individuals during fed conditions, while this new study measured the benefits of participants during fasting conditions.
Results of the recent study add another layer of substantiation that should help consumers feel confident that Capsimax is effective either with or without a meal.